Oncothyreon Inc. (Nasdaq: ONTY) announced the presentation of data highlighting the preclinical development of orally bioavailable, potent and selective checkpoint ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE